2023
DOI: 10.1096/fba.2023-00070
|View full text |Cite
|
Sign up to set email alerts
|

Profiling mitochondrial DNA mutations in tumors and circulating extracellular vesicles of triple‐negative breast cancer patients for potential biomarker development

Kunwar Somesh Vikramdeo,
Shashi Anand,
Sarabjeet Kour Sudan
et al.

Abstract: Early detection and recurrence prediction are challenging in triple‐negative breast cancer (TNBC) patients. We aimed to develop mitochondrial DNA (mtDNA)‐based liquid biomarkers to improve TNBC management. Mitochondrial genome (MG) enrichment and next‐generation sequencing mapped the entire MG in 73 samples (64 tissues and 9 extracellular vesicles [EV] samples) from 32 metastatic TNBCs. We measured mtDNA and cardiolipin (CL) contents, NDUFB8, and SDHB protein expression in tumors and in corresponding circulati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 59 publications
0
4
0
Order By: Relevance
“…In (42) we can see that, if α 1 = α 2 , the ratio the two conditional expectations becomes 1. Intuitively, α 1 = α 2 means the KB4 copula is exchangeable.…”
Section: Remarkmentioning
confidence: 90%
See 1 more Smart Citation
“…In (42) we can see that, if α 1 = α 2 , the ratio the two conditional expectations becomes 1. Intuitively, α 1 = α 2 means the KB4 copula is exchangeable.…”
Section: Remarkmentioning
confidence: 90%
“…From (42) it is clear that the ratio of two conditional expectations depends on some constant power of (1 + t). In order to satisfy Laplace approximation we need just only two conditions, which are…”
Section: As G (Smentioning
confidence: 99%
“…mtDNA could have implications for cancer diagnosis and treatment along with its direct effects on tumor onset and progression. For example, mtDNA mutations have been proposed as biomarkers for cancer 50,51 because of their stability and easy accessibility through various bodily fluids, including blood. Additionally, targeting mitochondrial metabolism could be a promising therapeutic strategy for cancer therapy.…”
Section: Discussionmentioning
confidence: 99%
“…We keep passive immunity as medium category. We did not subdivide this category under two types: natural immunity, received from the maternal side, and artificial immunity, received from medicine [34,39] as it is beyond the scope of this paper. In Figure 1 we have created an Erdos-Renyi random network of 30 agents where deep magenta, light magenta, white, lighter green, and deep green represent an agent with very low, somewhat low, medium, somewhat high and very high respectively [40,41].…”
Section: Assumption 1 the Following Set Of Assumptions Regarding The ...mentioning
confidence: 99%